NCT02449135

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography（DSA） for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 11, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 20, 2015

Completed
Last Updated

September 9, 2021

Status Verified

September 1, 2019

First QC Date

May 11, 2015

Last Update Submit

September 1, 2021

Conditions

Pancreatic Cancer

Keywords

Pancreatic CancerNano drug

Interventions

interventional therapyPROCEDURE

Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age:18-80
  • Karnofsky performance status \>60
  • Diagnosis of pancreatic cancer based on histology or the current accepted radiological measures.
  • Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
  • Will receive interventional therapy
  • Life expectancy: Greater than 3 months
  • Patients' routine blood test, liver function and kidney function have no obvious abnormalities
  • Ability to understand the study protocol and a willingness to sign a written informed consent document

You may not qualify if:

  • Patients with other primary tumor except pancreatic cancer
  • History of coagulation disorders or anemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central laboratory in Fuda cancer hospital

Guangzhou, Guangdong, 510000, China

Location

Related Publications (1)

  • Niu L, Chen J, Yao F, Zhou L, Zhang C, Wen W, Bi X, Hu Y, Piao X, Jiang F, Zeng J, Liu W, Li J, He L, Mu F, Zuo J, Xu K. Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis. Cryobiology. 2013 Oct;67(2):151-5. doi: 10.1016/j.cryobiol.2013.06.005. Epub 2013 Jun 24.

    PMID: 23806858BACKGROUND

Related Links

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • Lizhi Niu, PhD

    Fuda Cancer Hospital

    STUDY CHAIR

Study Design

Study Type
expanded access
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2015

First Posted

May 20, 2015

Last Updated

September 9, 2021

Record last verified: 2019-09

Locations

CN(1)